|
Synonyms: QL-1604 | QL1604
iparomlimab is an approved drug
Compound class:
Antibody
Comment: Iparomlimab (QL1604) is a humanized monoclonal antibody against programmed cell death protein 1 (PD-1). It blocks the inhibitory PD-1/PD-L1/2 immune checkpoint.
|
| No information available. |
Summary of Clinical Use  |
| Iparomlimab (QL1604) has been evaluated for safety and efficacy as a monotherapy for advanced solid tumours. The Chinese drug regulator (NMPA) approved the bifunctional combination (MabPair™ ; Zimbab®; coded as PSB205 or QL1706) of iparomlimab and tuvonralimab in October 2024, to treat recurrent or metastatic cervical cancer. The MabPair are produced together from a single cell line. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05801094 | A Phase I Study of QL1604 for Advanced Solid Tumors | Phase 1 Interventional | Qilu Pharmaceutical Co., Ltd. | 1 | |
| NCT06749899 | QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | Phase 3 Interventional | Sun Yat-sen University | ||
